Boston Scientific sales buoyed by 219% Taxus growth:
This article was originally published in Clinica
Executive Summary
Boston Scientific's sales rose by 49% to $1.6bn in the first quarter, as its Taxus drug-eluting stent generated growth of 219% to $686m. Sales of the device were $494m in the US, where it was launched in March 2004. The company's net income rose by 85% to $358m. "In the coming quarters, we expect our recent dramatic growth to return to more moderate levels, following a full year of Taxus system sales in the US", said president and CEO Jim Tobin. The company holds some 60% or more of the US DES market, with Johnson & Johnson its only commercial competitor to date (see page 13).
You may also be interested in...
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.